ClinicalTrials.gg
RecruitingNCT07219927Updated Oct 22, 2025

Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:

An observational study in Parkinson Disease, sponsored by Supernus Pharmaceuticals, Inc.. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-22.

Sponsored by Supernus Pharmaceuticals, Inc. · Observational

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
120
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 13 studies in Parkinson Disease by Supernus Pharmaceuticals, Inc. — 1 open to participants now, 2 under way, 1 of them phase 3. Parkinson Disease · Supernus Pharmaceuticals, Inc..

Started
2025
the only one that year
Observational
2 of 13
1 open now
Registered
13th of 13
by date

Among the 13 studies in Parkinson Disease by Supernus Pharmaceuticals, Inc., this one is the only one that started in 2025, is one of 2 observational ones, and was the 13th registered.

Parkinson Disease

4,576 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 13 studies in Parkinson Disease by Supernus Pharmaceuticals, Inc. is open now, in 1 country.

By country, each count listing its studies:

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 313 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Parkinson Disease by Supernus Pharmaceuticals, Inc., or all of them as a file.
02

Study summary

Real-World Participants Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: A Prospective, Phase 4, Multicenter, Observational Study in Parkinson's Disease

Read the detailed description

This observational study includes an Enrollment Day (participants enrolled any time between their prescription for the infusion and ONAPGO initiation); a Baseline Period (prior to ONAPGO initiation which includes in-home education on the use of ONAPGO by the Clinical Nurse Navigator [CNN] according to standard practice for patients with PD-prescribed ONAPGO); Dose Initiation, Titration, and Optimization per Prescription Periods; a Maintenance Period; Maintenance CNN standard of care visits; and an End-of-Study (EOS)/Discontinuation Visit.

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • ONAPGO
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants are eligible for participation in this study after they have received a prescription for Onapgo

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participant has received a prescription for ONAPGO™ according to the standard of care.

Participant has opted into receiving support services from the Clinical Nurse Navigator (CNN), a registered nurse specially trained to work with persons with Parkinson's disease, as noted on the Prescription Enrollment Form.

The HCP/Investigator determines the participant is an appropriate study participant.

Participant is able and willing to provide (or informed assent form [IAF], as applicable) and signs the consent form on the Enrollment Day.

Exclusion criteria

Exclusion Criteria:

Did not receive a prescription for ONAPGO™.

Prescribed ONAPGO™, but the HCP/Investigator determines the participant should not participate in this observational study.

Concomitant use of ONAPGO™ with 5-HT3 antagonists, including antiemetics (e.g., ondansetron, granisetron, dolasetron, palonosetron) or alosetron.

Known to apomorphine or to of ONAPGO™, including sulfite (e.g., sodium metabisulfite).

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
120 participants (estimated)
Patient registry
No

Interventions

  • OtherObservational study

    Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM)

06

What researchers measure

Primary outcomes

  1. Titration Duration and Time to Optimized Dose

    The time from the date of ONAPGO™ initiation to the date of Dose Optimization Confirmation, as documented by the HCP/Investigator Unit of Measure: days

    Time frame: Approximately 52-60 weeks

  2. Concomitant Parkinson's Disease (PD) Medication Adjustments

    Percentage of participants requiring ≥1 adjustment to their concomitant PD medications, as documented by the HCP/Investigator. "Percentage of participants"

    Time frame: Approximately 52-60 week

  3. The number of titration visits or dose adjustments required to reach the final optimized dose. This is a count of a specific event

    Number of titration visits or infusion adjustments to reach final optimized dose; Unit of Measure: count per participant

    Time frame: Approximately 52-60 weeks

Secondary outcomes

  1. Perception of Patient Global Health Improvement

    Change from baseline in the Patient Global Impression of Change (PGI-C) scale, with scores ranging from 1 ("very much improved") to 7 ("very much worse"); lower scores indicate better outcomes. Unit of Measure: PGI-C score (range 1-7)

    Time frame: Approximately 52-60 weeks

  2. Caregiver Burden

    Change from baseline in caregiver quality of life (QoL) as determined by scores on the European Quality of Life 5 Dimensions (EQ-5D) scale. This scale measures health-related QoL, with scores ranging from 0 (death) to 1 (full health). A higher score indicates a better outcome.

    Time frame: Approximately 52-60 weeks

  3. HCP/Investigator burden for ONAPGO providers

    Change from baseline to each time point in scores over time on the modified 8-item HCP Burden Scale to assess the HCP perceived burden of managing patients on ONAPGO treatment

    Time frame: Approximately 52-60 weeks

  4. Evaluation of ONAPGO usage during the maintenance period

    Hourly modal infusion rate (mg/hour) during the maintenance period Daily modal dose (mg/day) during the maintenance period Daily modal duration (hour) during the maintenance period

    Time frame: Approximately 52-60 weeks

  5. Safety by monitoring adverse events (AEs)

    Safety is measured by AE evaluation according to the standard of care and the percentage of participants who discontinue ONAPGO™ treatment due to AEs

    Time frame: Approximately 52-60 weeks

07

Study locations

5 of 5 sites recruiting
  • Parkinson's Disease and Movement Disorders Center - Orange County (South)
    Aliso Viejo, California 92656, United States
    Recruiting
    • Mindy Bixby, D.O. · Contact
    • Mindy Bixby, D.O. · Principal investigator
  • Parkinson's Disease and Movement Disorders Center - Orange County (North)
    Irvine, California 92618, United States
    Recruiting
    • Sandeep Thakkar, D.O. · Contact
    • Sandeep Thakkar, D.O. · Principal investigator
  • Parkinson's Research Centers of America - Palo Alto
    Palo Alto, California 94301, United States
    Recruiting
    • Salima Brillman, MD · Contact
    • Salima Brillman, MD · Principal investigator
  • Parkinson's Disease & Movement Disorders Center of Boca Raton
    Boca Raton, Florida 33486, United States
    Recruiting
    • Stuart Isaacson, MD · Contact
    • Stuart Isaacson, MD · Principal investigator
  • Parkinson's Disease and Movement Disorders Center - Long Island
    Commack, New York 11725, United States
    Recruiting
    • David Kreitzman, M.D. · Contact
    • David Kreitzman, M.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Aug 2027, 28 months after the start.

Of 60 industry-sponsored observational studies under Parkinson Disease, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's planned 28 months is below that.

Counting every sponsor, half of 440 studies reached it within 47 months; a quarter within 22 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2025
First posted
Oct 22, 2025
StartActual
Mar 31, 2025
Primary completionEst.
Aug 1, 2027
CompletionEst.
Aug 1, 2027
Last update
Oct 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07219927
Responsible party
Sponsor
First posted
Oct 22, 2025
Start date
Mar 31, 2025
Primary completion
Aug 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Oct 22, 2025

Study contacts

Mindy Grall, PhD ANP-BC
Contact
mgrall@supernus.com
18663980833
Supernus Supernus
Contact
18663980833
Mindy Grall, PhD ANP-BC
study chair · Supernus Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion